Search

Your search keyword '"Tjulandin, Sergei A."' showing total 371 results
Start Over Author "Tjulandin, Sergei A."
371 results on '"Tjulandin, Sergei A."'

3. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

Author

Aebi, Stephan, André, Fabrice, Barrios, Carlos, Bergh, Jonas, Bonnefoi, Herve, Bretel Morales, Denisse, Brucker, Sara, Burstein, Harold, Cameron, David, Cardoso, Fatima, Carey, Lisa, Chua, Boon, Ciruelos, Eva, Colleoni, Marco, Curigliano, Giuseppe, Delaloge, Suzette, Denkert, Carsten, Dubsky, Peter, Ejlertsen, Bent, Fitzal, Florian, Francis, Prudence, Galimberti, Viviana, Gamal El Din Mohamed Mahmoud, Hebatallah, Garber, Judy, Gnant, Michael, Gradishar, William, Gulluoglu, Bahadir, Harbeck, Nadia, Huang, Chiun-Sheng, Huober, Jens, Ilbawi, Andre, Jiang, Zefei, Johnston, Steven, Lee, Eun Sook, Loibl, Sibylle, Morrow, Monica, Partridge, Ann, Piccart, Martine, Poortmans, Philip, Prat, Aleix, Regan, Meredith, Rubio, Isabella, Rugo, Hope, Rutgers, Emiel, Sedlmayer, Felix, Semiglazov, Vladimir, Senn, Hans-Joerg, Shao, Zhiming, Spanic, Tanja, Tesarova, Petra, Thürlimann, Beat, Tjulandin, Sergei, Toi, Masakazu, Trudeau, Maureen, Turner, Nicholas, Vaz Luis, Inez, Viale, Giuseppe, Watanabe, Toru, Weber, Walter P., Winer, Eric P., Xu, Binghe, Burstein, H.J., Curigliano, G., Thürlimann, B., Weber, W.P., Poortmans, P., Regan, M.M., Senn, H.J., Winer, E.P., and Gnant, M.

Published
2021
Full Text
View/download PDF

5. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Author

Korach, Jacob, Huzarski, Tomasz, Byrski, Tomasz, Pautier, Patricia, Friedlander, Michael, Harter, Philipp, Colombo, Nicoletta, Pignata, Sandro, Scambia, Giovanni, Nicoletto, Maria, Nussey, Fiona, Clamp, Andrew, Penson, Richard, Oza, Amit, Poveda Velasco, Andrés, Rodrigues, Manuel, Lotz, Jean-Pierre, Selle, Frédéric, Ray-Coquard, Isabelle, Provencher, Diane, Prat Aparicio, Aleix, Vidal Boixader, Laura, Scott, Clare, Tamura, Kenji, Yunokawa, Mayu, Lisyanskaya, Alla, Medioni, Jacques, Pécuchet, Nicolas, Dubot, Coraline, De La Motte Rouge, Thibault, Kaminsky, Marie-Christine, Weber, Béatrice, Lortholary, Alain, Parkinson, Christine, Ledermann, Jonathan, Williams, Sarah, Banerjee, Susana, Cosin, Jonathan, Hoffman, James, Plante, Marie, Covens, Allan, Sonke, Gabe, Joly, Florence, Floquet, Anne, Hirte, Holger, Amit, Amnon, Park-Simon, Tjoung-Won, Matsumoto, Koji, Tjulandin, Sergei, Hoon Kim, Jae, Gladieff, Laurence, Sabbatini, Roberto, O'Malley, David, Timmins, Patrick, Kredentser, Daniel, Laínez Milagro, Nuria, Barretina Ginesta, Maria Pilar, Tibau Martorell, Ariadna, Gómez De Liaño Lista, Alfonso, Ojeda González, Belén, Mileshkin, Linda, Mandai, Masaki, Boere, Ingrid, Ottevanger, Petronella, Nam, Joo-Hyun, Filho, Elias, Hamizi, Salima, Cognetti, Francesco, Warshal, David, Dickson-Michelson, Elizabeth, Kamelle, Scott, McKenzie, Nathalie, Rodriguez, Gustavo, Armstrong, Deborah, Chalas, Eva, Celano, Paul, Behbakht, Kian, Davidson, Susan, Welch, Stephen, Helpman, Limor, Fishman, Ami, Bruchim, Ilan, Sikorska, Magdalena, Słowińska, Anna, Rogowski, Wojciech, Bidziński, Mariusz, Śpiewankiewicz, Beata, Casado Herraez, Antonio, Mendiola Fernández, César, Gropp-Meier, Martina, Saito, Toshiaki, Takehara, Kazuhiro, Enomoto, Takayuki, Watari, Hidemichi, Choi, Chel Hun, Kim, Byoung-Gie, Weon Kim, Jae, Hegg, Roberto, Vergote, Ignace, Poveda, Andrés, Ledermann, Jonathan A, Asher, Rebecca, Penson, Richard T, Oza, Amit M, Baldoni, Alessandra, Sonke, Gabe S, Kim, Jae-Hoon, Filho, Elias Abdo, Milenkova, Tsveta, Lowe, Elizabeth S, Rowe, Phil, and Pujade-Lauraine, Eric

Published
2021
Full Text
View/download PDF

8. Radiotherapy for Hepatocellular Carcinoma in Russia: a Survey-Based Analysis of Current Practice and the Impact of an Educational Workshop on Clinical Expertise

Author

Mitin, Timur, Degnin, Catherine, Chen, Yiyi, Shirvani, Shervin, Gillespie, Erin, Hoffe, Sarah, Latifi, Kujtim, Nabavizadeh, Nima, Dengina, Natalia, Chernich, Marina, Usychkin, Sergey, Kharitonova, Ekaterina, Egorova, Yulia, Pankratov, Alexandr, Tsimafeyeu, Ilya, Thomas, Jr, Charles R., Tjulandin, Sergei, and Likhacheva, Anna

Published
2020
Full Text
View/download PDF

9. Mutations in Mismatch Repair Genes and Microsatellite Instability Status in Pancreatic Cancer.

Author

Emelyanova, Marina, Ikonnikova, Anna, Pushkov, Alexander, Pudova, Elena, Krasnov, George, Popova, Anna, Zhanin, Ilya, Khomich, Darya, Abramov, Ivan, Tjulandin, Sergei, Gryadunov, Dmitry, and Pokataev, Ilya

Subjects
RESEARCH funding, GENETIC markers, IMMUNOTHERAPY, TUMOR markers, CANCER patients, PANCREATIC tumors, BIOINFORMATICS, METASTASIS, DNA repair, GENETIC mutation, SEQUENCE analysis, LYNCH syndrome II
Abstract

Simple Summary: Immunotherapy may be beneficial for pancreatic cancer (PC) patients with mismatch repair (MMR) deficiency. Although it is known that MMR deficiency (MMR-D) can result from mutations in MMR genes, the prevalence of these mutations and their impact on the formation of the MMR-D phenotype in PC have been insufficiently researched. Microsatellite instability (MSI) is a hallmark of MMR-D. Here, we estimated the frequency of germline and somatic mutations in the three MMR genes (MLH1, MSH2, and MSH6) in PC patients, estimated the prevalence of MSI, and assessed the relationship between MMR genes mutations and MSI status in PC. In our study of an unselected cohort of PC patients, we identified germline and somatic alterations in MMR genes, however these alterations did not contribute to the MMR-D phenotype. Our findings underscore the necessity of evaluating tumor MMR-D status in PC patients with confirmed Lynch syndrome when deciding whether to administer immunotherapy. Patients with pancreatic cancer (PC) showing mismatch repair (MMR) deficiency may benefit from immunotherapy. Microsatellite instability (MSI) is a hallmark of MMR deficiency (MMR-D). Here, we estimated the prevalence of MSI in PC, investigated germline and somatic mutations in the three MMR genes (MLH1, MSH2, and MSH6), and assessed the relationship between MMR genes mutations and MSI status in PC. Clinical specimens from PC patients were analyzed using targeted next-generation sequencing, including paired normal and tumor specimens from 155 patients, tumor-only specimens from 86 patients, and normal-only specimens from 379 patients. The MSI status of 235 PCs was assessed via PCR. Pathogenic/likely pathogenic (P/LP) germline variants in the MMR genes were identified in 1.1% of patients, while somatic variants were found in 2.6% of patients. No MSI-H tumors were detected. One patient carried two variants (P (VAF = 0.57) and LP (VAF = 0.25)) simultaneously; however, their germline/somatic status remains unknown due to the investigation focusing solely on the tumor and MSI analysis was not performed for this patient. MSI is rare in PC, even in tumors with MMR genes mutations. Our findings underscore the importance of assessing tumor MMR-D status in PC patients with confirmed Lynch syndrome when deciding whether to prescribe immunotherapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.

Author

Motzer, Robert J., Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E., Alekseev, Boris, Rha, Sun Young, Merchan, Jaime, Goh, Jeffrey C., Lalani, Aly-Khan A., De Giorgi, Ugo, Melichar, Bohuslav, Hong, Sung-Hoo, Gurney, Howard, Méndez-Vidal, María José, Kopyltsov, Evgeny, Tjulandin, Sergei, Gordoa, Teresa Alonso, and Kozlov, Vadim

Published
2024
Full Text
View/download PDF

11. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Catenacci, Daniel V T, Tebbutt, Niall C, Davidenko, Irina, Murad, André M, Al-Batran, Salah-Eddin, Ilson, David H, Tjulandin, Sergei, Gotovkin, Evengy, Karaszewska, Boguslawa, Bondarenko, Igor, Tejani, Mohamedtaki A, Udrea, Anghel A, Tehfe, Mustapha, De Vita, Ferdinando, Turkington, Cheryl, Tang, Rui, Ang, Agnes, Zhang, Yilong, Hoang, Tien, Sidhu, Roger, and Cunningham, David

Published
2017
Full Text
View/download PDF

13. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Author

Korach, Jacob, Huzarski, Tomasz, Byrski, Tomasz, Pautier, Patricia, Friedlander, Michael, Harter, Philipp, Colombo, Nicoletta, Pignata, Sandro, Scambia, Giovanni, Nicoletto, Maria, Nussey, Fiona, Clamp, Andrew, Penson, Richard, Oza, Amit, Poveda Velasco, Andrés, Rodrigues, Manuel, Lotz, Jean-Pierre, Selle, Frédéric, Ray-Coquard, Isabelle, Provencher, Diane, Prat Aparicio, Aleix, Vidal Boixader, Laura, Scott, Clare, Tamura, Kenji, Yunokawa, Mayu, Lisyanskaya, Alla, Medioni, Jacques, Pécuchet, Nicolas, Dubot, Coraline, de la Motte Rouge, Thibault, Kaminsky, Marie-Christine, Weber, Béatrice, Lortholary, Alain, Parkinson, Christine, Ledermann, Jonathan, Williams, Sarah, Banerjee, Susana, Cosin, Jonathan, Hoffman, James, Plante, Marie, Covens, Allan, Sonke, Gabe, Joly, Florence, Floquet, Anne, Hirte, Holger, Amit, Amnon, Park-Simon, Tjoung-Won, Matsumoto, Koji, Tjulandin, Sergei, Kim, Jae Hoon, Gladieff, Laurence, Sabbatini, Roberto, O'Malley, David, Timmins, Patrick, Kredentser, Daniel, Laínez Milagro, Nuria, Barretina Ginesta, Maria Pilar, Tibau Martorell, Ariadna, Gómez de Liaño Lista, Alfonso, Ojeda González, Belén, Mileshkin, Linda, Mandai, Masaki, Boere, Ingrid, Ottevanger, Petronella, Nam, Joo-Hyun, Filho, Elias, Hamizi, Salima, Cognetti, Francesco, Warshal, David, Dickson-Michelson, Elizabeth, Kamelle, Scott, McKenzie, Nathalie, Rodriguez, Gustavo, Armstrong, Deborah, Chalas, Eva, Celano, Paul, Behbakht, Kian, Davidson, Susan, Welch, Stephen, Helpman, Limor, Fishman, Ami, Bruchim, Ilan, Sikorska, Magdalena, Słowińska, Anna, Rogowski, Wojciech, Bidziński, Mariusz, Śpiewankiewicz, Beata, Casado Herraez, Antonio, Mendiola Fernández, César, Gropp-Meier, Martina, Saito, Toshiaki, Takehara, Kazuhiro, Enomoto, Takayuki, Watari, Hidemichi, Choi, Chel Hun, Kim, Byoung-Gie, Kim, Jae Weon, Hegg, Roberto, Vergote, Ignace, Pujade-Lauraine, Eric, Ledermann, Jonathan A, Gebski, Val, Penson, Richard T, Oza, Amit M, Poveda, Andrés, Fujiwara, Keiichi, Liu, Joyce, Lowe, Elizabeth S, and Bloomfield, Ralph

Published
2017
Full Text
View/download PDF

15. Bridging the Gap in Global Advanced Radiation Oncology Training: Impact of a Web-Based Open-Access Interactive Three-Dimensional Contouring Atlas on Radiation Oncologist Practice in Russia

Author

McClelland, III, Shearwood, Chernykh, Marina, Dengina, Natalia, Gillespie, Erin F., Likhacheva, Anna, Usychkin, Sergey, Pankratov, Alexandr, Kharitonova, Ekaterina, Egorova, Yulia, Tsimafeyeu, Ilya, Tjulandin, Sergei, Thomas, Jr, Charles R., and Mitin, Timur

Published
2019
Full Text
View/download PDF

18. Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study

Author

Pujol, Jean-Louis, De Pas, Tommaso, Rittmeyer, Achim, Vallières, Eric, Kubisa, Bartosz, Levchenko, Eugeny, Wiesemann, Sebastian, Masters, Gregory A., Shen, Robert, Tjulandin, Sergei A., Hofmann, Hans-Stefan, Vanhoutte, Nicolas, Salaun, Bruno, Debois, Muriel, Jarnjak, Silvija, De Sousa Alves, Pedro Miguel, Louahed, Jamila, Brichard, Vincent G., and Lehmann, Frédéric F.

Published
2016
Full Text
View/download PDF

23. Supplementary Table 5 from Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

Author

Prat, Aleix, primary, Bianchini, Giampaolo, primary, Thomas, Marlene, primary, Belousov, Anton, primary, Cheang, Maggie C.U., primary, Koehler, Astrid, primary, Gómez, Patricia, primary, Semiglazov, Vladimir, primary, Eiermann, Wolfgang, primary, Tjulandin, Sergei, primary, Byakhow, Mikhail, primary, Bermejo, Begoña, primary, Zambetti, Milvia, primary, Vazquez, Federico, primary, Gianni, Luca, primary, and Baselga, José, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Data from Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Author

Shah, Manish A., primary, Shitara, Kohei, primary, Lordick, Florian, primary, Bang, Yung-Jue, primary, Tebbutt, Niall C., primary, Metges, Jean-Phillippe, primary, Muro, Kei, primary, Lee, Keun-Wook, primary, Shen, Lin, primary, Tjulandin, Sergei, primary, Hays, John L., primary, Starling, Naureen, primary, Xu, Rui-Hua, primary, Sturtz, Keren, primary, Fontaine, Marilyn, primary, Oh, Cindy, primary, Brooks, Emily M., primary, Xu, Bo, primary, Li, Wei, primary, Li, Chiang J., primary, Borodyansky, Laura, primary, and Van Cutsem, Eric, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Table from Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Author

Shah, Manish A., primary, Shitara, Kohei, primary, Lordick, Florian, primary, Bang, Yung-Jue, primary, Tebbutt, Niall C., primary, Metges, Jean-Phillippe, primary, Muro, Kei, primary, Lee, Keun-Wook, primary, Shen, Lin, primary, Tjulandin, Sergei, primary, Hays, John L., primary, Starling, Naureen, primary, Xu, Rui-Hua, primary, Sturtz, Keren, primary, Fontaine, Marilyn, primary, Oh, Cindy, primary, Brooks, Emily M., primary, Xu, Bo, primary, Li, Wei, primary, Li, Chiang J., primary, Borodyansky, Laura, primary, and Van Cutsem, Eric, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Tables 1-2 and Supplementary Figures 1-2 from Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer

Author

Hingorani, Sunil R., primary, Harris, William P., primary, Beck, J. Thaddeus, primary, Berdov, Boris A., primary, Wagner, Stephanie A., primary, Pshevlotsky, Eduard M., primary, Tjulandin, Sergei A., primary, Gladkov, Oleg A., primary, Holcombe, Randall F., primary, Korn, Ronald, primary, Raghunand, Natarajan, primary, Dychter, Samuel, primary, Jiang, Ping, primary, Shepard, H. Michael, primary, and Devoe, Craig E., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure from Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Author

Shah, Manish A., primary, Shitara, Kohei, primary, Lordick, Florian, primary, Bang, Yung-Jue, primary, Tebbutt, Niall C., primary, Metges, Jean-Phillippe, primary, Muro, Kei, primary, Lee, Keun-Wook, primary, Shen, Lin, primary, Tjulandin, Sergei, primary, Hays, John L., primary, Starling, Naureen, primary, Xu, Rui-Hua, primary, Sturtz, Keren, primary, Fontaine, Marilyn, primary, Oh, Cindy, primary, Brooks, Emily M., primary, Xu, Bo, primary, Li, Wei, primary, Li, Chiang J., primary, Borodyansky, Laura, primary, and Van Cutsem, Eric, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Table 7 from Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

Author

Prat, Aleix, primary, Bianchini, Giampaolo, primary, Thomas, Marlene, primary, Belousov, Anton, primary, Cheang, Maggie C.U., primary, Koehler, Astrid, primary, Gómez, Patricia, primary, Semiglazov, Vladimir, primary, Eiermann, Wolfgang, primary, Tjulandin, Sergei, primary, Byakhow, Mikhail, primary, Bermejo, Begoña, primary, Zambetti, Milvia, primary, Vazquez, Federico, primary, Gianni, Luca, primary, and Baselga, José, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Table 3 from Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

Author

Prat, Aleix, primary, Bianchini, Giampaolo, primary, Thomas, Marlene, primary, Belousov, Anton, primary, Cheang, Maggie C.U., primary, Koehler, Astrid, primary, Gómez, Patricia, primary, Semiglazov, Vladimir, primary, Eiermann, Wolfgang, primary, Tjulandin, Sergei, primary, Byakhow, Mikhail, primary, Bermejo, Begoña, primary, Zambetti, Milvia, primary, Vazquez, Federico, primary, Gianni, Luca, primary, and Baselga, José, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Table 2 from Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

Author

Prat, Aleix, primary, Bianchini, Giampaolo, primary, Thomas, Marlene, primary, Belousov, Anton, primary, Cheang, Maggie C.U., primary, Koehler, Astrid, primary, Gómez, Patricia, primary, Semiglazov, Vladimir, primary, Eiermann, Wolfgang, primary, Tjulandin, Sergei, primary, Byakhow, Mikhail, primary, Bermejo, Begoña, primary, Zambetti, Milvia, primary, Vazquez, Federico, primary, Gianni, Luca, primary, and Baselga, José, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Table 4 from Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

Author

Prat, Aleix, primary, Bianchini, Giampaolo, primary, Thomas, Marlene, primary, Belousov, Anton, primary, Cheang, Maggie C.U., primary, Koehler, Astrid, primary, Gómez, Patricia, primary, Semiglazov, Vladimir, primary, Eiermann, Wolfgang, primary, Tjulandin, Sergei, primary, Byakhow, Mikhail, primary, Bermejo, Begoña, primary, Zambetti, Milvia, primary, Vazquez, Federico, primary, Gianni, Luca, primary, and Baselga, José, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Table 8 from Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

Author

Prat, Aleix, primary, Bianchini, Giampaolo, primary, Thomas, Marlene, primary, Belousov, Anton, primary, Cheang, Maggie C.U., primary, Koehler, Astrid, primary, Gómez, Patricia, primary, Semiglazov, Vladimir, primary, Eiermann, Wolfgang, primary, Tjulandin, Sergei, primary, Byakhow, Mikhail, primary, Bermejo, Begoña, primary, Zambetti, Milvia, primary, Vazquez, Federico, primary, Gianni, Luca, primary, and Baselga, José, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Methods, Figure Legends from Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

Author

Prat, Aleix, primary, Bianchini, Giampaolo, primary, Thomas, Marlene, primary, Belousov, Anton, primary, Cheang, Maggie C.U., primary, Koehler, Astrid, primary, Gómez, Patricia, primary, Semiglazov, Vladimir, primary, Eiermann, Wolfgang, primary, Tjulandin, Sergei, primary, Byakhow, Mikhail, primary, Bermejo, Begoña, primary, Zambetti, Milvia, primary, Vazquez, Federico, primary, Gianni, Luca, primary, and Baselga, José, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Table 1 from Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

Author

Prat, Aleix, primary, Bianchini, Giampaolo, primary, Thomas, Marlene, primary, Belousov, Anton, primary, Cheang, Maggie C.U., primary, Koehler, Astrid, primary, Gómez, Patricia, primary, Semiglazov, Vladimir, primary, Eiermann, Wolfgang, primary, Tjulandin, Sergei, primary, Byakhow, Mikhail, primary, Bermejo, Begoña, primary, Zambetti, Milvia, primary, Vazquez, Federico, primary, Gianni, Luca, primary, and Baselga, José, primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure 1 from Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

Author

Prat, Aleix, primary, Bianchini, Giampaolo, primary, Thomas, Marlene, primary, Belousov, Anton, primary, Cheang, Maggie C.U., primary, Koehler, Astrid, primary, Gómez, Patricia, primary, Semiglazov, Vladimir, primary, Eiermann, Wolfgang, primary, Tjulandin, Sergei, primary, Byakhow, Mikhail, primary, Bermejo, Begoña, primary, Zambetti, Milvia, primary, Vazquez, Federico, primary, Gianni, Luca, primary, and Baselga, José, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Table 6 from Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

Author

Prat, Aleix, primary, Bianchini, Giampaolo, primary, Thomas, Marlene, primary, Belousov, Anton, primary, Cheang, Maggie C.U., primary, Koehler, Astrid, primary, Gómez, Patricia, primary, Semiglazov, Vladimir, primary, Eiermann, Wolfgang, primary, Tjulandin, Sergei, primary, Byakhow, Mikhail, primary, Bermejo, Begoña, primary, Zambetti, Milvia, primary, Vazquez, Federico, primary, Gianni, Luca, primary, and Baselga, José, primary

Published
2023
Full Text
View/download PDF

37. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study

Author

Choueiri, Toni K, primary, Eto, Masatoshi, additional, Motzer, Robert, additional, De Giorgi, Ugo, additional, Buchler, Tomas, additional, Basappa, Naveen S, additional, Méndez-Vidal, María José, additional, Tjulandin, Sergei, additional, Hoon Park, Se, additional, Melichar, Bohuslav, additional, Hutson, Thomas, additional, Alemany, Carlos, additional, McGregor, Bradley, additional, Powles, Thomas, additional, Grünwald, Viktor, additional, Alekseev, Boris, additional, Rha, Sun Young, additional, Kopyltsov, Evgeny, additional, Kapoor, Anil, additional, Alonso Gordoa, Teresa, additional, Goh, Jeffrey C, additional, Staehler, Michael, additional, Merchan, Jaime R, additional, Xie, Ran, additional, Perini, Rodolfo F, additional, Mody, Kalgi, additional, McKenzie, Jodi, additional, and Porta, Camillo G, additional

Published
2023
Full Text
View/download PDF

39. A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer

Author

Tsimafeyeu, Ilya, primary, Statsenko, Galina, additional, Vladimirova, Liubov, additional, Besova, Natalia, additional, Raskin, Grigory, additional, Rykov, Ivan, additional, Mochalova, Anastasia, additional, Utyashev, Igor, additional, Gorbacheva, Svetlana, additional, Kazey, Vasily, additional, Gavrilova, Evgenia, additional, Dragun, Nadezhda, additional, Moiseyenko, Vladimir, additional, Tjulandin, Sergei, additional, and Artamonova, Elena, additional

Published
2023
Full Text
View/download PDF

43. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

Author

Gianni, Luca, Eiermann, Wolfgang, Semiglazov, Vladimir, Lluch, Ana, Tjulandin, Sergei, Zambetti, Milvia, Moliterni, Angela, Vazquez, Federico, Byakhov, Mikhail J, Lichinitser, Mikhail, Climent, Miguel Angel, Ciruelos, Eva, Ojeda, Belen, Mansutti, Mauro, Bozhok, Alla, Magazzù, Domenico, Heinzmann, Dominik, Steinseifer, Jutta, Valagussa, Pinuccia, and Baselga, Jose

Published
2014
Full Text
View/download PDF

48. Abstract 3481: Pharmacokinetics of alofanib and biomarker analysis in patients with advanced gastric cancer: A phase 1b study

Author

Raskin, Grigory, primary, Kazey, Vasily, additional, Gorbacheva, Svetlana, additional, Nikiforova, Aiyyna, additional, Statsenko, Galina, additional, Artamonova, Elena, additional, Vladimirova, Liubov, additional, Besova, Natalia, additional, Mochalova, Anastasia, additional, Rykov, Ivan, additional, Moiseyenko, Vladimir, additional, Utyashev, Igor, additional, Iugai, Sergei, additional, Dragun, Nadezhda, additional, Reznikov, Dmitry, additional, Gavrilova, Evgenia, additional, Tjulandin, Sergei, additional, and Tsimafeyeu, Ilya, additional

Published
2022
Full Text
View/download PDF

49. Alofanib in subsequent therapy for advanced gastric cancer: Final results from the phase Ib clinical trial.

Author

Tsimafeyeu, Ilya, primary, Vladimirova, Liubov Yu, additional, Mochalova, Anastasia, additional, Besova, Natalia, additional, Statsenko, Galina, additional, Rykov, Ivan, additional, Utyashev, Igor A., additional, Raskin, Grigory, additional, Kazey, Vasily, additional, Artamonova, Elena, additional, Moiseyenko, Vladimir, additional, and Tjulandin, Sergei, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results